Physician-reviewed guides on peptide therapy, weight loss, and longevity. Clear, clinical, and written for people deciding whether treatment is right for them.
Legitimate peptide therapy is physician-prescribed after a medical intake and dispensed by a licensed compounding pharmacy. This guide explains that status and process, and what separates it from research-use-only vendors.
ReadA plain walkthrough of the free 15-minute phone consult at Live Vital, what it covers, and why it sits before the medical intake rather than replacing it.
ReadA step-by-step look at how a licensed telehealth practice moves from medical intake to physician review to a compounded prescription, using Live Vital's process as the example.
ReadA plain walkthrough of how physician-prescribed peptide care works online, from the medical intake to the physician review, so you know what happens before you start.
ReadResearchers published the design of TTT1, an international Phase 3 trial testing whether adding a GLP-1 receptor agonist and an SGLT2 inhibitor to insulin helps overweight and obese adults with type 1 diabetes reach glucose targets. Because this is a design and methods paper, it explains how the study will be run rather than reporting any results.
ReadA study in Surgical Endoscopy used a nationwide health records database to track how bariatric surgery use and pre-surgery GLP-1 medication use shifted between 2018 and 2025. It found surgery volumes dropped after 2022 while more surgery patients had taken a GLP-1 first, with clear differences by race, insurance, and hospital.
ReadA 2024-era review in European Heart Journal summarizes current drug and lifestyle strategies for peripheral artery disease and notes emerging data on GLP-1 receptor agonists. It is a synthesis of existing evidence, not a new trial, and it describes treatment categories rather than promising results for any individual.
ReadA claims-based study emulating a clinical trial found that adults without diabetes or cardiovascular disease who used semaglutide had a lower one-year risk of developing diabetes than those who used liraglutide, with no detectable difference in cardiovascular events. The findings are observational and cannot prove cause and effect.
ReadMedPage Today reported troubling findings from a study of GLP-1 compounders. The headline is real, but the details are thin, so here is how to read it without overreacting.
ReadA Healthcare Brew report flags that some telehealth GLP-1 prescriptions come with thin clinician oversight and light regulation. Here is what that reporting establishes, what it does not, and what it means if you are considering legitimate physician-prescribed care.
ReadDr. Taylor cuts through the noise on injectable peptides — what the evidence actually supports, who qualifies, and how to stay safe. A clinically grounded patient guide.
ReadDr. Taylor breaks down the latest real-world tirzepatide vs semaglutide weight loss study and what it means for your treatment decision. Telehealth consult available.
ReadDr. Taylor breaks down this week's peptide therapy news, helping patients separate clinical evidence from hype before their next telehealth visit.
ReadDr. Taylor breaks down new real-world data on tirzepatide vs semaglutide weight loss — and what it means for patients deciding between these two medications.
ReadDr. Taylor cuts through the political noise on peptide therapy reclassification 2025, explaining real clinical and access implications for current and new patients.
ReadDr. Taylor cuts through the social media hype on BPC-157 peptide therapy safety, giving patients an honest risk-benefit framework grounded in real clinical evidence.
ReadDr. Taylor cuts through the noise on peptide therapy. Get a clinically grounded framework to decide if injectable peptides are right for your health goals.
ReadDr. Taylor explains the latest evidence on GLP-1 de-escalation vs. lifelong use, so patients can make informed decisions about stopping semaglutide after weight loss.
ReadDr. Taylor explains what the FDA's compounded semaglutide deadline means for telehealth patients and how to protect your access before the window closes.
ReadDr. Taylor breaks down the FDA's compounded semaglutide ban, what it means for telehealth GLP-1 patients, and how to protect your treatment plan going forward.
ReadDr. Taylor cuts through the 2026 regulatory noise to explain which peptides are at risk, which are newly legitimized, and what you should do right now.
ReadDr. Taylor cuts through social media hype to give patients an evidence-based framework for evaluating peptide therapy side effects, safety, and FDA regulatory shifts.
ReadDr. Taylor unpacks new genetic and pharmacological research to help patients understand why GLP-1 response varies — and what to do before giving up on therapy.
ReadPeptides span a wide range, from compounds with decades of clinical study to newer ones still under investigation. Here is how to think about that spectrum and how physician-prescribed care fits in.
ReadA practical guide to preparing for a conversation about physician-prescribed peptide therapy, including what these compounds are and how care is accessed through a medical intake and physician review.
ReadA practical guide to telling credible peptide information from noise, and how physician-prescribed treatment actually works through a medical intake and review.
ReadA plain look at the different delivery formats for physician-prescribed testosterone therapy, and how legitimate access begins with a medical intake and physician review rather than a retail purchase.
ReadAn experimental gut-lining peptide called larazotide acetate has renewed interest in whether peptides can support the intestinal barrier. Here is how physician-reviewed peptide care actually works, and what to sort out before anything is prescribed.
ReadPeptides and anabolic steroids are different classes of molecules that work through different mechanisms, and this piece explains that distinction for readers considering legal, physician-prescribed peptide care through telehealth.
ReadA plain look at the two most discussed GLP-1 medications, how they differ mechanically, and how physician-prescribed care through a telehealth intake actually works.
ReadDihexa is an investigational peptide drawing attention for its potential role in cognitive function. Here is how physician-prescribed care works and what a cautious reader should ask before starting anything.
ReadA physician-led look at why the idea of a required sequence between mitochondrial peptides is a misconception, and how licensed telehealth actually decides what any one person is a candidate for.
ReadA wearable notification about breathing disturbances is a prompt, not a diagnosis. This piece explains how to interpret it, what confirming a diagnosis actually involves, and where physician-reviewed care fits.
ReadA practical look at how a nationwide telehealth practice reviews and prescribes care through a medical intake, and what to know before you start.
ReadAn overview of how GLP-1 receptor agonists intersect with metabolic health and fertility conversations for women with obesity or insulin resistance, and how physician-prescribed care is accessed through a medical intake.
ReadA practical guide for readers weighing direct-to-consumer prescription brands, focused on what physician review and a real medical intake actually mean.
ReadA plain look at what people mean by microdosing GLP-1 medications, why dosing is a clinical decision, and how physician-prescribed GLP-1 care is accessed through a medical intake at Live Vital.
ReadComing back to a GLP-1 after months away, including after pregnancy, is a medical decision that a physician makes at re-intake. Here is how the restart conversation actually works and why past dosing rarely maps onto a new start.
ReadA physician-led look at how compounded GLP-1 medications work through licensed telehealth, why price-shopping vendors is the wrong first step, and what it may mean when a current medication is not producing the response you expected.
ReadLL-37 is an antimicrobial peptide drawing growing interest in the telehealth space. Here is how prescription peptide care actually works, from medical intake to physician review, and what to consider before you start.
ReadEvery protocol at Live Vital is physician-prescribed after a medical intake and physician approval. Outcomes vary by individual.